Lexicon Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Lexicon Pharmaceuticals Stock Forecast and Price Target
The average price target for Lexicon Pharmaceuticals's stock of $4.50 recently provided by two leading analysts would represent a 172.73% upside from its last closing price if reached. This potential increase is based on a high estimate of $10.00 and a low estimate of $2.00. If you are looking to invest in the stock, it's important to research and compare different companies.
172.73% Upside
Lexicon Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Lexicon Pharmaceuticals's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $1.77, which would mean an increase of 100.00%. Over the next ten years, experts predict that Lexicon Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$151.18 | Buy/Sell | $174.55 | 12.45% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.05 | Buy/Sell | CHF105.00 | 20.85% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.29 | Buy/Sell | $118.92 | 19.01% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$80.89 | Buy/Sell | $92.47 | 18.06% |
| BSX Stock Forecast | Boston Scientific | Buy |
11
|
$72.21 | Buy/Sell | $70.14 | 13.56% |
Lexicon Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Lexicon Pharmaceuticals's Revenue has gone down from $24.00M to $140.00k – a 99.42% drop. For next year, analysts predict Revenue of $57.88M, which would mean an increase of 41242.86%. Over the next nine years, experts predict that Lexicon Pharmaceuticals's Revenue will grow at a rate of 820150.00%.
.jpg)
Lexicon Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Lexicon Pharmaceuticals's EBITDA has decreased by 41.52%, going from $-171.55M to $-100.33M. In the next year, analysts believe that EBITDA will reach $-168.64M – an increase of 68.09%. For the next seven years, experts predict that Lexicon Pharmaceuticals's EBITDA will grow at a rate of 32.44%.
Lexicon Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Lexicon Pharmaceuticals's EBIT has decreased from $-173.29M to $-100.76M – a 41.85% drop. In the next year, analysts believe that EBIT will reach $-179.02M – an increase of 77.67%. In 2030, the professionals' prediction is that LXRX's EBIT will decrease by 941.38%, reaching $847.77M.
Lexicon Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Lexicon Pharmaceuticals's EPS has grown by 100.00%, rising from $-1.72 to $0.00. For next year, analysts predict EPS of $-0.74, which would mean an increase of 100.00%. Over the next ten years, experts predict that Lexicon Pharmaceuticals's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)